Suppression of inter-ictal spikes by CM40907. A double-blind placebo-controlled investigation and review of spike counting as a methodology for assessing the antiepileptic effect of drugs

Epilepsy Res. 1990 Apr;5(3):247-50. doi: 10.1016/0920-1211(90)90046-x.

Abstract

To assess the efficacy of CM40907--a new antiepileptic drug--in suppressing inter-ictal spikes, 6 patients with severe intractable epilepsy and frequent spikes in their inter-ictal EEGs were entered in a double-blind placebo-controlled trial. The results show that CM40907 is efficacious in reducing spike counts in the first hour after oral administration. The results of the study are presented and inter-ictal spike counting as a method is discussed.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anticonvulsants / therapeutic use*
  • Double-Blind Method
  • Electroencephalography*
  • Epilepsy / diagnosis
  • Epilepsy / drug therapy*
  • Epilepsy / physiopathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Placebos
  • Pyridazines / therapeutic use*

Substances

  • Anticonvulsants
  • Placebos
  • Pyridazines
  • CM 40907